YALE NEW HAVEN HOSPITAL
1. Target Overview & Investment Thesis
YALE NEW HAVEN HOSPITAL is a 1306-bed large academic medical center in NEW HAVEN, CT with $3.45B in net patient revenue and a -15.7% operating margin. The hospital serves a payer mix of 22.5% Medicare, 24.0% Medicaid, and 53.5% commercial.
Thesis: Undervalued. Our ML models identify $253.6M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -15.7% to -8.3% (+736bps).
| Net Revenue HCRIS | $3.45B |
| Current EBITDA COMPUTED | $-540.8M |
| Operating Margin COMPUTED | -15.7% |
| Occupancy HCRIS | 84.7% |
| Revenue / Bed COMPUTED | $2.6M |
| Net-to-Gross HCRIS | 29.8% |
| Distress Probability ML | 46.7% |
2. Market Context & Competitive Position
CT has 39 Medicare-certified hospitals with a median operating margin of -6.8%. The target's margin of -15.7% places it below the state median. Among 137 size-comparable peers (653-2612 beds), the median margin is -5.2%. The target's below-peer margin suggests operational improvement opportunity.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (653-2612), prioritizing same-state peers. 137 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| YALE NEW HAVEN HOSPITAL (Target) | CT | 1306 | $3.45B | -15.7% |
| NYU LANGONE HOSPITALS | NY | 1618 | $7.24B | -7.8% |
| STANFORD HEALTH CARE | CA | 657 | $6.76B | 3.7% |
| CLEVELAND CLINIC HOSPITAL | OH | 1326 | $6.38B | -17.7% |
| VANDERBILT UNIVERSITY MEDICAL | TN | 1084 | $5.44B | -15.9% |
| UCSF MEDICAL CENTER | CA | 834 | $5.44B | -5.4% |
| UT MD ANDERSON CANCER CENTER | TX | 721 | $4.90B | -0.8% |
| UNIV OF MI HOSPITALS & HLTH CT | MI | 951 | $4.62B | -1.4% |
| CEDARS-SINAI MEDICAL CENTER | CA | 908 | $3.92B | -5.5% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $253.6M (736bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $72.4M | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $68.9M | +200bp | 12mo |
| Denial Rate Reduction | 12.0% | 6.5% | $68.2M | +198bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $41.9M | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $2.2M | +6bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $-540.8M |
| + RCM Uplift | +$253.6M |
| Pro Forma EBITDA | $-287.2M |
| Current Margin | -15.7% |
| Pro Forma Margin | -8.3% |
| WC Released (1x) | $132.2M |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $-832.0M | $-1.03B | 0.00x | -100.0% |
| Base (11x exit) | 10.0x | 11.0x | $-832.0M | $-1.40B | 0.00x | -100.0% |
| Bull Case | 9.0x | 11.0x | $-748.8M | $-837.6M | 0.00x | -100.0% |
| Bull (12x exit) | 9.0x | 12.0x | $-748.8M | $-1.13B | 0.00x | -100.0% |
| Bear Case | 11.0x | 10.0x | $-915.2M | $-2.03B | 0.00x | -100.0% |
| Bear (11x exit) | 11.0x | 11.0x | $-915.2M | $-2.53B | 0.00x | -100.0% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| High | Negative operating margin | RCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion |
| Medium | Elevated Medicaid exposure (24.0%) | Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 137 hospitals with 653-2612 beds
- Same-state prioritization (n=2)
- Comp margins: P25=-16.1% / P50=-5.2% / P75=4.1%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.